Jump to:
Bivictrix Therapeutics PLC Fundamentals
| Company Name | Bivictrix Therapeutics PLC | Last Updated | 2024-05-16 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 82.526 m | Market Cap | £9.49 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.04 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0564 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.2207 | Cash Equity Ratio | 0.6723 |
|---|
| Quick Ratio | 5.2029 | Current Ratio | 6.85 |
|---|
| Price To Book Value | 3.3512 | ROCE | 0 |
|---|
Bivictrix Therapeutics PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Bivictrix Therapeutics PLC Company Financials
| Assets | 2022 | 2021 |
|---|
| Tangible Assets | £571,000.00 | £339,000.00 |
| Intangible Assets | 0 | 0 |
| Investments | 0 | 0 |
| Total Fixed Assets | £571,000.00 | £339,000.00 |
| Stocks | 0 | 0 |
| Debtors | 0 | 0 |
| Cash & Equivalents | £3.29 m | £6.06 m |
| Other Assets | 0 | 0 |
| Total Assets | £4.54 m | £6.88 m |
| Liabilities | 2022 | 2021 |
|---|
| Creditors within 1 year | £391,000.00 | £379,000.00 |
| Creditors after 1 year | £188,000.00 | £175,000.00 |
| Other Liabilities | 0 | 0 |
| Total Liabilities | £579,000.00 | £554,000.00 |
| Net assets | £3.96 m | £6.33 m |
| Equity | 2022 | 2021 |
|---|
| Called up share capital | £661,000.00 | £661,000.00 |
| Share Premium | £12.05 m | £12.05 m |
| Profit / Loss | -£2.97 m | -£2.53 m |
| Other Equity | £3.96 m | £6.33 m |
| Preference & Minorities | 0 | 0 |
| Total Capital Employed | £3.96 m | £6.33 m |
| Ratios | 2022 | 2021 |
|---|
| Debt Ratio | £0.05 | £0.03 |
| Debt-to-Equity | £0.05 | £0.03 |
| Assets / Equity | 1.2207 | 1.2207 |
| Cash / Equity | 0.6723 | 0.6723 |
| EPS | -£0.04 | -£0.05 |
| Cash Flow | 2022 | 2021 |
|---|
| Cash from operating activities | -£2.40 m | -£1.78 m |
| Cashflow before financing | -£2.40 m | £5.25 m |
| Increase in Cash | -£2.78 m | £5.20 m |
| Income | 2022 | 2021 |
|---|
| Turnover | 0 | 0 |
| Cost of sales | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Profit | -£2.98 m | -£1.89 m |
| Pre-Tax profit | -£2.97 m | -£2.53 m |
Bivictrix Therapeutics PLC Company Background
| Sector | Healthcare |
|---|
| Activities | BiVictriX Therapeutics PLC is a drug development company. It has developed its proprietary Bi-Cygni technology which utilizes Antibody Drug Conjugates for the treatment of various cancers including Acute Myeloid Leukaemia. The Group has one reportable segment, being the development of pharmaceutical products within the United Kingdom. |
|---|
| Latest Interim Date | 19 Sep 2023 |
|---|
| Latest Fiscal Year End Date | 24 May 2024 |
|---|
Bivictrix Therapeutics PLC Directors
| Appointed | Name | Position |
|---|
| 2024-03-28 | Dr. Michael Glen Kauffman, M.D.,PhD | Non-Executive Director,Chairman |
| 2023-12-05 | Mr. Iain Gladstone Ross | Non-Executive Director |
| 2023-03-30 | Ms. Susan Day Lowther | Non-Executive Director |
| 2023-03-30 | Ms. Tiffany Jane Thorn | Executive Director,Chief Executive Officer |
| 2024-03-28 | Professor Robert Edward Hawkins | Non-Executive Director |
| 2024-03-28 | Mr. William Drummond Paris | Non-Executive Director,Senior Independent Non-Executive Director |
Bivictrix Therapeutics PLC Contact Details
Bivictrix Therapeutics PLC Advisors
